+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Left atrial appendage closure with WATCHMAN in Asian patients: 2 year outcomes from the WASP registry

      a , * , 1 , b , c , d , e , f , g , h , h , i

      International Journal of Cardiology. Heart & Vasculature


      BMI, body mass index, CI, confidence interval, LAA, left atrial appendage, NOAC, Novel oral anticoagulant, NVAF, non-valvular atrial fibrillation, OAC, oral anticoagulation, SAE, serious adverse events, SE, systemic embolism, TOE, transoesophageal echocardiography, TIA, transient ischaemic attack, WASP, The Asia-Pacific Registry on WATCHMAN Outcomes in Real-Life Utilization, Atrial fibrillation, Ischaemic stroke, Left atrial appendage, LAA device closure, Anticoagulant therapy

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.



          Left atrial appendage closure is a non-pharmacological alternative for stroke prevention in high-risk non-valvular atrial fibrillation patients, but has not been widely studied in Asian patients. The prospective WASP registry assessed real-world outcomes for patients undergoing WATCHMAN implant in the Asia-Pacific region.


          Data were collected from consecutive patients across 9 centres. Major endpoints included procedural success, safety and long-term outcomes including occurrence of bleeding, stroke/transient ischaemic attack/systemic embolism and all-cause mortality.


          Subjects ( n = 201) had a mean age of 70.8 ± 9.4 years, high stroke risk (CHA 2DS 2-VASc: 3.9 ± 1.7), elevated bleeding risk (HAS-BLED: 2.1 ± 1.2) with 53% patients from Asian countries. Successful implantation occurred in 98.5% of patients; 7-day device/procedure-related SAE rate was 3.0%. After 2 years of follow-up, the rates of ischaemic stroke/TIA/SE and major bleeding were 1.9 and 2.2 per 100-PY, respectively, representing relative reductions of 77% and 49% versus expected rates per risk scores. The relative risk reductions versus expected rates were more pronounced in Asians vs. Non-Asians (89% vs 62%; 77% vs 14%). Other significant findings included larger mean LAA ostium diameter for Asians vs. Non-Asians (23.4 ± 4.1 mm vs. 21.2 ± 3.2 mm, p < 0.001) and hence requirement for larger median device size (27 mm for Asians, 24 mm for non-Asians [ p < 0.0001]).


          Real-world experience of left atrial appendage closure with WATCHMAN has demonstrated low peri-procedural risk, and long-term efficacy for stroke and bleeding prevention in a primarily Asian cohort.

          Graphical abstract

          Related collections

          Most cited references 14

          • Record: found
          • Abstract: found
          • Article: not found

          Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis.

          The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic therapy (warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in nonvalvular atrial fibrillation (NVAF) requires continued evaluation.
            • Record: found
            • Abstract: found
            • Article: not found

            Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.

            Left atrial appendage (LAA) occlusion with WATCHMAN has emerged as viable alternative to vitamin K antagonists in randomized controlled trials.
              • Record: found
              • Abstract: found
              • Article: not found

              Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation

              Supplemental Digital Content is available in the text.

                Author and article information

                Int J Cardiol Heart Vasc
                Int J Cardiol Heart Vasc
                International Journal of Cardiology. Heart & Vasculature
                09 April 2019
                June 2019
                09 April 2019
                : 23
                [a ]HeartCare Partners, GenesisCare, Brisbane, Australia
                [b ]Medistra Hospital, Jakarta, Indonesia
                [c ]South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia
                [d ]MonashHEART, Monash Health, Melbourne, Australia
                [e ]Queen Elizabeth Hospital, Hong Kong
                [f ]Yonsei University Health System, Seoul, Republic of Korea
                [g ]Ramathibodi Hospital, Bangkok, Thailand
                [h ]Boston Scientific Corp., Minneapolis, MN, USA
                [i ]National Heart Institute, Kuala Lumpur, Malaysia
                Author notes
                [* ]Corresponding author at: Suite 212, Ramsay Specialist Centre, Greenslopes Private Hospital, Newdegate Street, Brisbane 4120, Australia. Karen.Phillips@

                This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

                S2352-9067(19)30027-2 100358
                © 2019 The Authors

                This is an open access article under the CC BY-NC-ND license (

                Original Paper


                Comment on this article